Market Place
Sourcing Support
Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial
12 Nov 2024 //
BUSINESSWIRE
BIOTECanada Welcomes Three New Members to its Board of Directors
09 Oct 2024 //
BUSINESSWIRE
Astrazeneca Amyloidosis Commitment: 2024 Isa Symposium Data Presented
23 May 2024 //
BUSINESSWIRE
Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand
16 May 2024 //
ENDPTS
AZ`s Alexion debuts short film highlighting NMOSD community
18 Apr 2024 //
FIERCE PHARMA
Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya
08 Apr 2024 //
GLOBENEWSWIRE
Alexion Canada Appoints Karen Heim as New General Manager
02 Apr 2024 //
BIOSPACE
FDA expands AZ`s Ultomiris to NMOSD after prior rejection
26 Mar 2024 //
FIERCE PHARMA
Voyager asset lands on planet Alexion after Pfizer handoff
06 Nov 2023 //
FIERCE BIOTECH
Alexion data at Joint ECTRIMS-ACTRIMS Meeting showcase impact of C5 inhibition
11 Oct 2023 //
PRESS RELEASE
SEC charges former Alexion VP Joseph Dupont with insider trading
30 Jun 2023 //
FIERCE PHARMA
Alexion touts early `proof-of-concept` data for Neurimmune antibody
22 May 2023 //
ENDPTS
Alexion advances commitment to transform outcomes in rare neurological diseases
02 Mar 2023 //
BUSINESSWIRE
NICE recommends Alexion’s asfotase alfa across England
27 Jan 2023 //
PHARMATIMES
AstraZeneca`s Alexion hopes to extend dominance in PNH
16 Dec 2022 //
FIERCEBIOTECH
ASH: Roche records rare disease win ahead of Soliris showdown
12 Dec 2022 //
FIERCEBIOTECH
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio
16 Nov 2022 //
BUSINESSWIRE
JP Morgan splashes into the life sciences,tapping Stephen Squinto to run venture
01 Nov 2022 //
ENDPTS
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS
12 Oct 2022 //
ASTRAZENECA-US
EC approves Alexion’s Ultomiris for generalised myasthenia gravis
27 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
AstraZeneca`s Complementary PNH Treatment Hits the Mark in Phase III
17 Sep 2022 //
BIOSPACE
Argenx`s Vyvgart and Alexion`s Ultomiris Go Toe-to-Toe in Myasthenia Gravis
24 Aug 2022 //
PRNEWSWIRE
Xencor Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
On a roll, AstraZeneca flags looming approvals for three big drug franchises
26 Jul 2022 //
ENDPTS
Alexion puts €65M forward to strengthen its position on the Emerald Isle
27 Jun 2022 //
ENDPTS
AstraZeneca earmarks $68.7M for two Alexion plants in Ireland
24 Jun 2022 //
FIERCEPHARMA
UCB details positive pivotal data for myasthenia gravis
10 May 2022 //
ENDPTS
AstraZeneca Revenues up 56% in the Quarter.
09 May 2022 //
CONTRACTPHARMA
AstraZeneca Plans New R&D Center and Alexion Headquarters
02 May 2022 //
CONTRACTPHARMA
AZ`s rare disease rising star Ultomiris snags 3rd FDA nod
29 Apr 2022 //
FIERCEPHARMA
AstraZeneca`s Alexion, Arvinas nab space at new biotech tower
16 Apr 2022 //
FIERCEBIOTECH
AstraZeneca pays $775M to settle patent dispute over Alexion drug
18 Mar 2022 //
BIOPHARMADIVE
Roche, AstraZeneca settle Ultomiris patent lawsuit
19 Feb 2022 //
FIERCEPHARMA
Argenx`s Vyvgart is already winning neurologist support
17 Feb 2022 //
FIERCEPHARMA
Alexion and UK patient advocacy groups launch video campaign
16 Feb 2022 //
PHARMATIMES
Roche Unit, AstraZeneca’s Alexion Settle Ultomiris Patent Suit
16 Feb 2022 //
BLOOMBERGLAW
AZ`s R&D chiefs talk roxadustat, Imfinzi-treme
10 Feb 2022 //
FIERCEPHARMA
n-Lorem Receives $1M Donation From Alexion for Individualized Medicines
27 Jan 2022 //
BUSINESSWIRE
AstraZeneca picks up new weapon in fight with Alnylam and Pfizer
08 Jan 2022 //
CAMBRIDGEINDEPENDENT
AZ reportedly blocked buyout of rare disease specialist Sobi
03 Dec 2021 //
FIERCEPHARMA
Alexion kids` books aim to help parents explain rare diseases
29 Oct 2021 //
FIERCEPHARMA
AZN plucks PhIII drug for Alexion’s rare disease pipeline
30 Sep 2021 //
ENDPTS
AstraZeneca to buy rare-disease specialist Caelum in potential $500 million deal
28 Sep 2021 //
REUTERS
ICER Publishes Evidence Report on Treatments for Myasthenia Gravis
10 Sep 2021 //
FIRSTWORDPHARMA
Apellis announces mixed results in eye disease tests
10 Sep 2021 //
ENDPTS
AstraZeneca lays out the red carpet for rare disease drug Alexion paid $855M for
26 Aug 2021 //
ENDPTS
Ultomiris chalks up first flop since AZ`s Alexion buy
21 Aug 2021 //
FIERCEPHARMA
Canadian agency loses a battle in effort to force a drug maker
05 Aug 2021 //
STAT
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
26 Jul 2021 //
PHARMATIMES
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
26 Jul 2021 //
PHARMATIMES
Alexion`s Ultomoris is on track for another blockbuster year
20 Jul 2021 //
FIERCEPHARMA
Alexion touts new PhIII data of Soliris successor as AstraZeneca takeover looms
17 Jul 2021 //
ENDPTS
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS
15 Jul 2021 //
BUSINESS WIRE
UK nod paves way for AstraZeneca-Alexion deal to close next week
15 Jul 2021 //
ENDPTS
AZ scores final clearance for Alexion acquisition in the UK
13 Jul 2021 //
PHARMATIMES
European Commission clears AstraZeneca`s $39B bid for Alexion
07 Jul 2021 //
ENDPTS
AstraZeneca`s Alexion acquisition cleared by European Commission
06 Jul 2021 //
SHARECAST
Alexion Wins Treasury Award for Technology Transformation, Using ICD
15 Jun 2021 //
PRNEWSWIRE
Caelum and Alexion Present Phase 2 Data on Safety and Tolerability of CAEL-101
11 Jun 2021 //
BUSINESSWIRE
Caelum and Alexion Present Phase 2 Data on Safety and Tolerability of CAEL-101
11 Jun 2021 //
BUSINESSWIRE
